<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02728518</url>
  </required_header>
  <id_info>
    <org_study_id>NHI-01</org_study_id>
    <nct_id>NCT02728518</nct_id>
  </id_info>
  <brief_title>Nebulized Amikacin Versus Intravenous Amikacin in the Treatment of Nosocomial Pneumonia</brief_title>
  <official_title>Evaluation of the Safety and Efficacy of Nebulized Amikacin as Adjunctive Therapy in Hospital Acquired and Ventilator Associated Bacterial Pneumonia in Surgical Intensive Care Units</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart Institute, Egypt</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Heart Institute, Egypt</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigator's goal in this study is to evaluate the efficacy and safety of nebulized
      amikacin versus intravenous amikacin in patients with hospital and ventilator acquired
      pneumonia in surgical patients admitted to the intensive care units infected with gram
      negative bacilli
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      prospective, randomized, controlled study on post-cardiac surgery patients , included two
      groups, over one year period. The first group was administered intravenous (IV) amikacin 20
      mg/kg once daily. The second group was prescribed amikacin nebulizer 400 mg twice daily. Both
      groups were co-administered intravenous (IV) piperacillin/tazobactam empirically.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of cured patients in the nebulized amikacin group versus the proportion of cured patients in the intravenous group</measure>
    <time_frame>through study completion, over one year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">133</enrollment>
  <condition>Pneumonia</condition>
  <arm_group>
    <arm_group_label>Nebulized Amikacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients in this arm will take amikacin nebulizer 400 mg twice daily in addition to standard beta lactam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amikacin Intravenous</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients in this arm will take intravenous (IV) amikacin 20 mg/kg once daily in addition to standard beta lactam</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebulized Amikacin</intervention_name>
    <description>400mg twice daily nebulized amikacin</description>
    <arm_group_label>Nebulized Amikacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous Amikacin</intervention_name>
    <description>20mg/kg once daily intravenous amikacin</description>
    <arm_group_label>Amikacin Intravenous</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients admitted to ICU

          -  Clinical suspicion of VAP or HAP defined by a new persistent radiological infiltrate
             and one of the following signs:

          -  purulent tracheal aspirations, or

          -  temperature of 38Â° or higher, or leucocyte count &gt; 10000/ml or

          -  Positive culture sensitive to amikacin

          -  In case of empirical treatment, risk of multi resistant bacteria defined as follows:

          -  Antimicrobial therapy in preceding 90 days and

          -  Current hospitalization of 5 d or more

        Exclusion Criteria:

          -  History of Asthma

          -  Multi organ failure or any psychiatric illness

          -  allergy to amikacin or intolerance to nebulized amikacin

          -  Myasthenia gravis.

          -  Severely impaired renal function (creatinine clearance lower than 10 mL/min or renal
             replacement therapy)

          -  Vestibulo-cochlear disease.

          -  Pregnancy.

          -  Brain death
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nehal A Hassan, BCPS</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Heart Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Faten F El sayed, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Heart Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nirmeen A Sabry, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Pharmacy Cairo University</affiliation>
  </overall_official>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2016</study_first_submitted>
  <study_first_submitted_qc>April 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2016</study_first_posted>
  <last_update_submitted>August 23, 2016</last_update_submitted>
  <last_update_submitted_qc>August 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Heart Institute, Egypt</investigator_affiliation>
    <investigator_full_name>NKhalek</investigator_full_name>
    <investigator_title>Pharmacotherapy Specialist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amikacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>September 16, 2017</submitted>
    <returned>October 17, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

